UCB (OTCMKTS:UCBJY) Shares Down 9.3% – Here’s What Happened

UCB SA (OTCMKTS:UCBJY)’s stock price fell 9.3% during mid-day trading on Friday . The company traded as low as $129.55 and last traded at $129.55. 1,261 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 36,031 shares. The stock had previously closed at $142.88.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on UCBJY shares. Zacks Research upgraded UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research report on Monday, June 22nd. Finally, Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

UCB Price Performance

The firm has a fifty day simple moving average of $143.74 and a two-hundred day simple moving average of $147.55. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.